Clearmind Medicine Inc. (CMND) company profile
Close on Nov 13, 2026Market cap $716.08KP/E –Yield –
About Clearmind Medicine
Pharmaceutical Preparations, SIC 2834
Clearmind Medicine Inc. is a clinical-stage pharmaceutical company focused on the development of novel therapies for central nervous system disorders. The company's primary focus is on developing 5-methoxy-2-aminoindane (MEAI), an investigational psychedelic substance intended to treat alcohol use disorder, obesity, metabolic disorders, depression, and addiction. Because its therapeutic candidates are currently undergoing preclinical and clinical development, the company has not commercialized any products or technologies and has not generated revenue from product sales.
Clearmind is incorporated in British Columbia, Canada, and maintains its principal executive offices in Vancouver, British Columbia. The company conducts part of its operations through wholly-owned subsidiaries located in Canada and Israel, specifically Clearmind Labs Corp. in Canada and Clearmindmed Ltd. in Israel. Its common shares trade on The Nasdaq Stock Market LLC.
Summary of the business section of Clearmind Medicine's latest annual report, written by StockData.
Company profile
Company
- Legal name
- Clearmind Medicine Inc.
- Headquarters
- Vancouver, British Columbia, Z4
- Address
- 101-1220 West 6th Avenue V6H1A5
- Phone
- 972-54-5704749
- Website
- clearmindmedicine.com
- Employees
- 2, Oct 31, 2025
- Industry
- Pharmaceutical Preparations
- Incorporated in
- Z4
- Fiscal year ends
- October 31
- Auditor
- Brightman Almagor Zohar & Co., Tel Aviv, Israel
Stock & identifiers
- Ticker
- CMND
- Exchange
- Nasdaq
- IPO date
- Nov 16, 2022
- Shares outstanding
- 0M, Jan 19, 2026
- Filer category
- Non-accelerated filer<br>Emerging growth company
- Stock splits
- 1-for-8 reverse, Oct 5, 2026; 1-for-10 reverse, May 21, 2026; 1-for-40 reverse, Dec 15, 2025; 1-for-30 reverse, Nov 28, 2023
- SEC CIK
- 1892500
- CUSIP
- 185053709
- ISIN
- CA1850537095
- FIGI
- BBG01237P3C8
- Share class FIGI
- BBG00KWY2X19
- EIN
- 00-0000000
Executives and directors
Officers and directors who filed ownership reports (Forms 3, 4, 5) in the last two years
No recent ownership filings by officers or directors
Clearmind Medicine's leadership is listed in its proxy statement (Form DEF 14A).
IPO
From the final prospectus (Form 424B4) and the first day of trading
Offering
- Type
- Initial public offering
- Final prospectus filed
- Nov 16, 2022
- Offer price
- $6.50
- Exchange
- Nasdaq
- Lock-up ends (est.)
- May 15, 2023
“Per Common Share Total Initial public offering price $ 6.50 $ 7,500,005.50 Underwriting discounts and commissions (1) $ 0.59 $ 675,000 Proceeds to us (before expenses) $ 5.91 $ 6,825,005.50 (1) We have agreed to reimburse the underwriter for certain expenses and the underwriter will receive compensation in addition to und”
Lock-up end is estimated as 180 days after the first trading day; the prospectus sets the actual terms.
Corporate history
Events identified from SEC filings
| Date | Event | Details |
|---|---|---|
| Nov 16, 2022 | IPO | Initial public offering priced (424B4 prospectus) |
| Nov 9, 2022 | Listing | Registration of securities on an exchange (Form 8-A) |
See a number that looks wrong?